Critical Survey: Corvus Pharmaceuticals (NASDAQ:CRVS) & Sangamo Therapeutics (NASDAQ:SGMO)

Corvus Pharmaceuticals (NASDAQ:CRVS) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.

Earnings and Valuation

This table compares Corvus Pharmaceuticals and Sangamo Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28 million	($0.52)	-22.58
Sangamo Therapeutics	$39.55 million	1.78	-$122.93 million	($0.38)	-0.45

Corvus Pharmaceuticals has higher earnings, but lower revenue than Sangamo Therapeutics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Corvus Pharmaceuticals and Sangamo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Institutional & Insider Ownership

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Corvus Pharmaceuticals and Sangamo Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1	0	6	0	2.71
Sangamo Therapeutics	2	1	1	0	1.75

Corvus Pharmaceuticals presently has a consensus price target of $33.33, indicating a potential upside of 183.93%. Sangamo Therapeutics has a consensus price target of $5.50, indicating a potential upside of 3,135.29%. Given Sangamo Therapeutics’ higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Corvus Pharmaceuticals.

Risk and Volatility

Corvus Pharmaceuticals has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.

Summary

Corvus Pharmaceuticals beats Sangamo Therapeutics on 7 of the 13 factors compared between the two stocks.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.